Clear all

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

1,131 results found

Article
Ask Lexy

Fenwick & West LLP | USA | 19 Jan 2023

2022 Corporate Governance Practices and Trends

Differences in their stage of development, including the relative importance placed on various business objectives (for example, focus on growth and…
Article
Ask Lexy

Taylor Wessing | United Kingdom | 18 Jan 2023

Global pharma groups Eli Lilly and AbbVie withdraw from UK’s branded medicines voluntary scheme

The Associate of the British Pharmaceutical Industry (ABPI) announced on 16 January that two global pharmaceutical companies, Eli Lilly and AbbVie…
Article
Ask Lexy

Pearce IP | Australia | 16 Jan 2023

BioBlast® w/e 13 Jan 23: Alvotech’s golimumab, Alvotech and Fuji commercialisation partnership, Dong-A ST’s ustekinumab, Coherus and Klinge’s deal for US aflibercept, Boan Biotech and CP Qingdao denosumab deal, Rani and Celltrion’s oral ustekinumab biosimilar

Korea Biomedical Review reported that Dong-A STl has published the results of its global Ph III trials of DMB-3115 (biosimilar ustekinumab). Dong-A…
Article
Ask Lexy

Gowling WLG | Canada | 16 Jan 2023

Life sciences in Canada: 2022 year in review highlights

Canadian Courts issued many life sciences decisions in 2022. This article summarizes a number of the more notable court decisions, as well as other…
Article
Ask Lexy

Venable LLP | USA | 12 Jan 2023

Venable’s BiologicsHQ Monthly Injection - December 2022

BiologicsHQ's "Spotlight On" product dashboards provide, at a glance, an overview of the status of U.S. patent proceedings. The dashboards concerning…
Article
Ask Lexy

Smart & Biggar | Canada, Global | 12 Jan 2023

Canadian Patent law 2022: A Year in Review

2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for…
Article
Ask Lexy

K&L Gates LLP | USA | 6 Jan 2023

Perrigo Co. v. AbbVie Inc. - Third Circuit Holds Mutual Release Bars Generic Drug Company's Antitrust Claim Alleging that "Sham" Patent Infringement Litigation Delayed Generic Drug Launch

On 21 July 2022, the Third Circuit in Perrigo Co. v. AbbVie Inc. affirmed the district court's judgment that the mutual release in the settlement…
Article
Ask Lexy

Smart & Biggar | Canada | 4 Jan 2023

2022 Highlights in Canadian Life Sciences IP and Regulatory Law

The Federal Courts released the following patent decisions in 2022, all relating to s. 6(1) actions under the Patented Medicines (Notice of…
Previous page 1 2 3 ...